Mabwell, a biopharmaceutical company, and WuXi XDC, a global contract research, development, and manufacturing organization (CRDMO), signed a letter of intent (LOI) for long-term strategic collaboration on Mabwell’s multiple adaptive antibody–drug conjugates (ADC) projects.

Mabwell has had multiple products in clinical studies or preclinical research using its ADC technology platforms and CMC development capabilities.

In a statement, WuXi XDC said that it will make further efforts to accelerate global layout of Mabwell’s R&D and commercialization, cost reduction and R&D efficiency improvement by their leading antibody-drug conjugate production technology platform and integration capabilities.